Navelbine (Vinorelbine Tartrate)

Navelbine is a Vinca‑alkaloid antineoplastic used in specific solid‑tumour pathways.

• Non‑small cell lung cancer: helps control disease progression and may improve survival when used in combination chemotherapy regimens.
• Metastatic breast cancer: used to reduce tumour burden and delay disease progression in patients with advanced disease.

• Vinorelbine tartrate binds to tubulin, inhibiting microtubule polymerisation during the mitotic phase. This disruption prevents proper spindle formation, causing cell‑cycle arrest at metaphase and ultimately leading to apoptosis of rapidly dividing cancer cells.

Navelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Neutropenia: reduced white‑blood‑cell count increasing infection risk.
• Anemia: lowered red‑blood‑cell levels causing fatigue.
• Constipation: decreased bowel motility.
• Alopecia: hair loss that may be temporary.
• Fatigue: general tiredness during treatment.

Serious or Rare Side Effects

• Severe neutropenia or febrile neutropenia: requires urgent medical attention.
• Pulmonary toxicity: dyspnoea or interstitial lung changes.
• Hypersensitivity reactions: rash, pruritus, or anaphylaxis.
• Cardiac toxicity: arrhythmias or reduced cardiac function.
• Peripheral neuropathy: tingling or numbness in extremities.

Before initiating Navelbine, clinicians should assess baseline health status and monitor patients throughout therapy.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: evaluate hepatic enzymes as vinorelbine is metabolised hepatically.
• Evaluate for infection: postpone dosing if active severe infection is present.
• Adjust for renal impairment: consider dose modification in patients with reduced kidney function.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Vinorelbine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Concurrent radiotherapy to the same site: heightened risk of tissue toxicity.

Moderate Interactions (Monitor Closely)

• Other myelosuppressive agents (e.g., cyclophosphamide): additive bone‑marrow suppression.
• Anticoagulants (e.g., warfarin): potential for increased bleeding risk.
• CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise plasma levels.